Your Manufacturing Milestones Matter.
Specialized to manufacture oral solid dose (OSD) forms, Alcami’s Wilmington, North Carolina site supports preclinical production through commercial launch and supply. Our cGMP manufacturing technologies, including low/high shear granulation and fluid bed drying capabilities, are arranged in flexible suites to support novel, advanced, and complex projects. 

In addition to OSD development and manufacturing, Alcami’s in-house analytical, stability, and packaging services provide an integrated and custom-tailored offering to help your product reach patients sooner.

Alcami expanded its Science, Technology, Engineering, Arts, and Math (STEAM) education initiatives this fall with three specialized outreach events designed to encourage high school and college students to pursue careers in chemistry, engineering, and other STEAM fields. 

On October 30, 2018, Divine Savior Holy Angels High School (DSHA) students got a behind-the-scenes look at Alcami’s Germantown, Wisconsin active pharmaceutical ingredient (API) Center of Excellence, as part of the company’s ongoing efforts to promote women in STEAM careers. The all-girls engineering class toured the campus, met with key female company leaders, and learned about potential career paths through interactive presentations.

The nonprofit Honor Flight Network honors America’s military veterans for their sacrifices by transporting as many of them as possible to see the Washington, D.C. memorials of the wars they fought in, at no cost to them. Alcami employee and Vietnam veteran, Herman Anthony, was recently selected for an Honor Flight, and was accompanied by Milwaukee Brewers all-star relief pitcher, Corey Knebel. Herman received a hero’s welcome at the Milwaukee airport from Alcami colleagues, friends, family, and the general public. He recently spoke with Alcami's Marketing & Corporate Communications team to discuss his experience.

Stephan Kutzer, Ph.D., President & CEO of Alcami Corporation, has been elected to serve as 1st Vice President of the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT) beginning November 1, 2018. Together with the ten other members of DCAT’s Board of Directors, Dr. Kutzer will help develop and guide the organization’s strategic plan in a manner to best serve the organization’s 500+ member companies.

Durham, NC (USA) – October 25, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, announced today its collaboration with Medicines Development for Global Health (MDGH), a not-for-profit Australian biopharmaceutical company dedicated to the development of affordable medicines and vaccines for neglected diseases prevalent in low and middle-income countries. MDGH recently received U.S. Food and Drug Administration (FDA) approval of moxidectin, a novel new drug for the treatment of river blindness (onchocerciasis). MDGH utilized Alcami’s advanced analytical testing services and industry-leading accelerated turnaround time offering to meet critical approval deadlines.

Project Call 1.0 Proposal Selected by NIIMBL Governing Committee

Durham, NC (USA) – August 30, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, and the University of North Carolina Wilmington (UNCW), North Carolina’s globally-minded research and development university, today announce they have been awarded an educational grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), an organization comprised of companies, educational institutions, nonprofits, and state governments dedicated to accelerating biopharmaceutical manufacturing innovation, developing industry standards, and educating and training a pipeline of skilled workers for the field’s abundant well-paying jobs. The grant will fund the UNCW program “Partnership for Workforce Development in the Biopharmaceutical Industry,” which will be co-developed and taught by Alcami subject matter experts.

Durham, NC (USA) – July 18, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced a renewed partnership with the Wisconsin Department of Natural Resources (DNR) to revitalize and repair the Hank Aaron State Trail in Milwaukee, Wisconsin, and the Pike Lake Hiking Trail in Hartford, Wisconsin. Volunteers from Alcami’s Germantown, Wisconsin Center of Excellence for active pharmaceutical ingredient (API) development, scale-up, and commercialization will work alongside Wisconsin DNR trail coordinators and park superintendents to renovate the popular state trails.

Durham, NC (USA) – June 14, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, announced today its $15,000 donation to the Wilmington, North Carolina Fire Department (WFD) to help fund IvyGene® cancer screenings for firefighters. Wilmington Mayor Bill Saffo, Mayor Pro-tem Margaret Haynes, Deputy Fire Chief Jon S. Mason, and other prominent city officials accepted the donation at an invitation-only commemorative event Wednesday, June 13, 2018, at Alcami’s Wilmington state-of-the-art advanced laboratory services and oral solid dose formulation and manufacturing facilities.

Durham, NC (USA) – June 13, 2018 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced the expanded deployment of its Extended Workbench laboratory services program to support the ongoing manufacturing and development of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension). ZILRETTA is the first U.S. Food and Drug Administration (FDA) approved product from Flexion Therapeutics, Inc., a Massachusetts-based biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). Flexion utilized Alcami’s Extended Workbench to support ZILRETTA from Phase 2 clinical trials through commercial launch and is using the program for the release and stability testing of commercial batches.

Durham, NC (USA) – June 1, 2018 – Alcami Corporation (“Alcami” or the “Company”), a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced it has reached an agreement to be acquired by Madison Dearborn Partners, LLC (MDP). MDP, a leading private equity firm based in Chicago, will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation (NASDAQ: ARCC) (“Ares Capital”). Alcami’s management team, led by Chief Executive Officer, President, and Chairman, Dr. Stephan Kutzer, will continue to guide the Company. The transaction is expected to be completed in the third quarter of 2018, pending customary closing conditions.